Advanced Inhalation Therapies (AIT) Ltd. entered into a definitive agreement to acquire KokiCare, Inc. (OTCPK:KKIC.D) in a reverse merger transaction on December 29, 2016. As part of consideration, KokiCare will issue 11.6 million ordinary shares and 0.8 million Series A preferred shares and these preferred shares can be converted into an equal number of ordinary shares. Advanced Inhalation Therapies will also acquire 0.5 million Ordinary Shares and promissory notes convertible into 1.4 million ordinary shares outstanding. Advanced Inhalation Therapies (AIT) Ltd. was considered as the accounting acquirer as per the terms of the transaction. Advanced Inhalation Therapies (AIT) Ltd obtained $10.2 million finance from Investors. KokiCare will operate as wholly-owned subsidiary of Advanced Inhalation Therapies. The transaction is subject to regulatory approvals, government approval and third party consents. KokiCare, Inc. changed its name to AIT Therapeutics, Inc. effective January 9, 2016. AIT’s ticker "KKIC" will change to the ticker symbol on the 20th business day. As a result of the merger, the former business plan and management of AIT Therapeutics, Inc., previously known as KokiCare, have been replaced with the business and management team of Advanced Inhalation Therapies (AIT) Ltd. comprising of Ron Bentsur as Executive Chairman of the Board of Directors, Amir Avniel as President and Chief Executive Officer and Director, Yossef Av-Gay as Chief Scientific Officer and Director, Racheli Vizman as Chief Operation Officer, David Grossman as Director, Ari Raved as Director, Jerome B. Zeldis as Director and Steven A. Lisi as Director. Jason Lane, executive officer AIT Therapeutics, Inc. resigned at time of closing. Upon closing the Merger, AIT executive office will be in Rehovot, Israel office of AIT Ltd. Gilbert J. Bradshaw of Wilson & Oskam, LLP acted as legal advisor for AIT Therapeutics, Inc. Craig V. Butler of Law Offices of Craig V. Butle acted as legal advisor for Advanced Inhalation Therapies (AIT) Ltd. Advanced Inhalation Therapies (AIT) Ltd. completed the acquisition of AIT Therapeutics, Inc. (OTCPK:KKIC.D) in a reverse merger transaction on January 13, 2017.